Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Ian Hirsch"'
Autor:
Elizabeth R. Brown, Youyi Fong, Kathleen M. Neuzil, Holly Janes, Shu Han, Peter B. Gilbert, Iksung Cho, Yunda Huang, Michael P. Fay, Lindsay N. Carpp, An Vandebosch, Thomas R. Fleming, Martha Nason, David Benkeser, Marco Carone, Ying Huang, Paula W. Annunziato, Alex Luedtke, Jonathan Hartzel, Ian Hirsch, Deborah Donnell, Michal Juraska, Myron S. Cohen, Honghong Zhou, Devan V. Mehrotra, Ollivier Hyrien, Dean Follmann, Lawrence Corey
Publikováno v:
Annals of Internal Medicine
Safe and effective vaccines are a critical component in the control of COVID-19. A group of industry, government, and academic researchers discuss pragmatic issues in the choice and interpretation of clinical endpoints for evaluating efficacy in COVI
Publikováno v:
Annals of Allergy, Asthma & Immunology. 125:171-176
Background Blood eosinophil count (BEC) measurements are a noninvasive, relatively reliable surrogate marker for eosinophilic airway inflammation. Single measurements of peripheral BEC greater than or equal to 150 cells/μL predict the response to an
Publikováno v:
Annals of Allergy, Asthma & Immunology. 124:79-86
Background Fixed airflow obstruction (FAO) is associated with severe eosinophilic asthma. Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody for patients with severe, uncontrolled eosinophilic asthma. Objective W
Publikováno v:
Advances in Therapy
Introduction For patients with eosinophilic asthma with allergic characteristics, understanding the key drivers of exacerbations is important to identify optimal treatment strategies. Benralizumab is an interleukin-5 receptor alpha–directed cytolyt
Autor:
Ann R, Falsey, Magdalena E, Sobieszczyk, Ian, Hirsch, Stephanie, Sproule, Merlin L, Robb, Lawrence, Corey, Kathleen M, Neuzil, William, Hahn, Julie, Hunt, Mark J, Mulligan, Charlene, McEvoy, Edwin, DeJesus, Michael, Hassman, Susan J, Little, Barbara A, Pahud, Anna, Durbin, Paul, Pickrell, Eric S, Daar, Larry, Bush, Joel, Solis, Quito Osuna, Carr, Temitope, Oyedele, Susan, Buchbinder, Jessica, Cowden, Sergio L, Vargas, Alfredo, Guerreros Benavides, Robert, Call, Michael C, Keefer, Beth D, Kirkpatrick, John, Pullman, Tina, Tong, Margaret, Brewinski Isaacs, David, Benkeser, Holly E, Janes, Martha C, Nason, Justin A, Green, Elizabeth J, Kelly, Jill, Maaske, Nancy, Mueller, Kathryn, Shoemaker, Therese, Takas, Richard P, Marshall, Menelas N, Pangalos, Tonya, Villafana, Antonio, Gonzalez-Lopez, Barry S, Zingman
Publikováno v:
The New England Journal of Medicine
The New England journal of medicine, vol 385, iss 25
The New England journal of medicine, vol 385, iss 25
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been
Publikováno v:
TP10. TP010 CLINICAL AND POPULATION-LEVEL STUDIES OF ASTHMA.
Autor:
Huashi Li, Dean Billheimer, J. Kwiatek, Xingnan Li, Paul Newbold, Ian Hirsch, Eugene R. Bleecker, Rohit Katial, Deborah A. Meyers
Publikováno v:
TP10. TP010 CLINICAL AND POPULATION-LEVEL STUDIES OF ASTHMA.
Autor:
Devan V. Mehrotra, Lindsey R. Baden, Lindsay N. Carpp, Jonathan Fintzi, Ying Huang, Myron S. Cohen, Thomas R. Fleming, David Benkeser, Hana M. El Sahly, Michal Juraska, Ian Hirsch, Peter B. Gilbert, Shu Han, Alex Luedtke, Lawrence Corey, Martha Nason, Kathleen M. Neuzil, Holly Janes, Marco Carone, Michael P. Fay, Youyi Fong, James G. Kublin, Yunda Huang, Erin E. Gabriel, Deborah Donnell, Honghong Zhou, Ollivier Hyrien, An Vandebosch, Iksung Cho, Dean Follmann
Publikováno v:
medRxiv
article-version (status) pre
article-version (number) 1
article-version (status) pre
article-version (number) 1
Background: Several candidate vaccines to prevent COVID-19 disease have entered large-scale phase 3 placebo-controlled randomized clinical trials and some have demonstrated substantial short-term efficacy. Efficacious vaccines should, at some point,
Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma
Autor:
Gary T. Ferguson, James Zangrilli, Ian Hirsch, Joel N. Kline, Njira L Lugogo, Frank Trudo, Mitchell Goldman, Geoffrey Chupp
Publikováno v:
Annals of Allergy, Asthma & Immunology. 122:478-485
Background Benralizumab is a unique eosinophil-depleting monoclonal antibody that significantly reduces asthma exacerbations, improves lung function and asthma symptoms, and permits the reduction of maintenance oral corticosteroid dosage for patients
Publikováno v:
Journal of Asthma and Allergy. 12:21-33
Background Patients with severe, uncontrolled asthma experience debilitating symptoms that result in meaningful reductions to health-related quality of life. Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody that